Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801744 | 1.00 | TYR (0.58) | TYR | |
| SCHEMBL6616210 | 0.81 | TYR (0.58) | TYR | |
| SCHEMBL6610278 | 0.81 | TYR (0.58) | TYR | |
| SCHEMBL6813350 | 0.80 | TYR (0.59) | TYR | |
| SCHEMBL6611879 | 0.80 | TYR (0.59) | TYR | |
| SCHEMBL6611367 | 0.79 | TYR (0.61) | TYR | |
| SCHEMBL6615054 | 0.79 | TYR (0.61) | TYR | |
| SCHEMBL6615736 | 0.79 | TYR (0.58) | TYR | |
| SCHEMBL6611964 | 0.79 | TYR (0.58) | TYR | |
| SCHEMBL6613419 | 0.78 | MEN1 (0.63) | TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | claimed |
| EP-1381359-A1 | AURONES AS TELOMERASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-21 | — | — | EP | claimed |
| WO-2002083123-A1 | AURONES AS TELOMERASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-10-24 | — | — | WO | claimed |
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | disclosed |
| EP-1381359-A1 | AURONES AS TELOMERASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002083123-A1 | AURONES AS TELOMERASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132807-A1 | Aurones as telomerase inhibitors | TERT, TERF2, TERF2IP | TYR 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.